Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated COVID-19 vaccine (Vero cells)
- Development stage
- Unknown
- Lead developer
- Beijing Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Inactivated COVID-19 vaccine (Vero cells) refers to a class of vaccines developed using traditional inactivated virus technology. The process involves culturing the SARS-CoV-2 virus in Vero cells (African green monkey kidney cells), followed by inactivation using β-propiolactone to ensure the virus cannot replicate while maintaining its antigenic integrity. These vaccines are typically formulated with an aluminum hydroxide adjuvant to enhance the immune response. Major examples include the vaccines developed by Sinopharm's Beijing Institute of Biological Products (COVILO) and Sinovac Biotech (CoronaVac). These vaccines have been widely used globally and received Emergency Use Listing (EUL) from the World Health Organization for the prevention of COVID-19 in various age groups.
- Brand names
- COVILOCoronaVacHayat-Vax
- Other names
- Sinopharm COVID-19 vaccineSinovac COVID-19 vaccineSARS-CoV-2 Vaccine (Vero Cell), InactivatedBIBP-CorV
02
Targets
SARS-CoV-2 spikeN (Nucleocapsid protein)M protein (SARS-CoV-2 membrane protein)E (Tick-borne encephalitis virus envelope protein)
Beyond the preview
Go deeper on inactivated COVID-19 vaccine (Vero cells).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated COVID-19 vaccine (Vero cells).